Literature DB >> 15606901

Pathogenic mutations inactivate parkin by distinct mechanisms.

Iris H Henn1, Johanna M Gostner, Peter Lackner, Jörg Tatzelt, Konstanze F Winklhofer.   

Abstract

Loss of parkin function is the major cause of autosomal recessive Parkinson's disease (ARPD). A wide variety of parkin mutations have been identified in patients; however, the pathophysiological mechanisms leading to the inactivation of mutant parkin are poorly understood. In this study we characterized pathogenic C- and N-terminal parkin mutants and found distinct pathways of parkin inactivation. Deletion of the C terminus abrogated the association of parkin with cellular membranes and induced rapid misfolding and aggregation. Four N-terminal missense mutations, located within the ubiquitin-like domain (UBL), decrease the stability of parkin; as a consequence, these mutants are rapidly degraded by the proteasome. Furthermore, we present evidence that a smaller parkin species of 42 kDa, which is present in extracts prepared from human brain and cultured cells, originates from an internal start site and lacks the N-terminal UBL domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606901     DOI: 10.1111/j.1471-4159.2004.02854.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  44 in total

Review 1.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

2.  Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP.

Authors:  Angelika S Rambold; Margit Miesbauer; Doron Rapaport; Till Bartke; Michael Baier; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  Mol Biol Cell       Date:  2006-05-17       Impact factor: 4.138

Review 3.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

4.  Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase Parkin.

Authors:  Fabienne C Fiesel; Thomas R Caulfield; Elisabeth L Moussaud-Lamodière; Kotaro Ogaki; Daniel F A R Dourado; Samuel C Flores; Owen A Ross; Wolfdieter Springer
Journal:  Hum Mutat       Date:  2015-06-03       Impact factor: 4.878

5.  Differential interaction of the E3 ligase parkin with the proteasomal subunit S5a and the endocytic protein Eps15.

Authors:  Susan S Safadi; Gary S Shaw
Journal:  J Biol Chem       Date:  2009-10-29       Impact factor: 5.157

6.  Policing Parkin with a UblD.

Authors:  Fen Liu; Kylie J Walters
Journal:  EMBO J       Date:  2011-07-20       Impact factor: 11.598

7.  The E3 ubiquitin ligase parkin is recruited to the 26 S proteasome via the proteasomal ubiquitin receptor Rpn13.

Authors:  Miguel A Aguileta; Jelena Korac; Thomas M Durcan; Jean-François Trempe; Michael Haber; Kalle Gehring; Suzanne Elsasser; Oliver Waidmann; Edward A Fon; Koraljka Husnjak
Journal:  J Biol Chem       Date:  2015-02-09       Impact factor: 5.157

8.  UbMES and UbFluor: Novel probes for ring-between-ring (RBR) E3 ubiquitin ligase PARKIN.

Authors:  Sungjin Park; Peter K Foote; David T Krist; Sarah E Rice; Alexander V Statsyuk
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

9.  HSPA1A-independent suppression of PARK2 C289G protein aggregation by human small heat shock proteins.

Authors:  Melania Minoia; Corien Grit; Harm H Kampinga
Journal:  Mol Cell Biol       Date:  2014-07-14       Impact factor: 4.272

10.  Monitoring PARKIN RBR Ubiquitin Ligase Activation States with UbFluor.

Authors:  Peter K Foote; Alexander V Statsyuk
Journal:  Curr Protoc Chem Biol       Date:  2018-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.